Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy Research Letter

   

Authors:	Mohan, M.; Janz, S.; Brazauskas, R.; Dwinell, M. B.; Teng, B. Q.; Yun, G.; Dong, J.; Pasquini, M. C.; Giralt, S.; Landau, H.; Stadtmauer, E.; Krishnan, A.; D’Souza, A.
Title:	Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
Keywords:	adult; cancer survival; controlled study; treatment response; middle aged; major clinical study; overall survival; lenalidomide; thalidomide; cancer patient; letter; protein blood level; disease association; progression free survival; quality of life; bortezomib; multiple myeloma; maintenance therapy; dexamethasone; hematopoietic stem cell transplantation; age; cytokine; chemokine; gamma interferon; scoring system; upregulation; cancer control; gamma interferon inducible protein 10; gender; growth factor; transplantation, autologous; autologous hematopoietic stem cell transplantation; race; tumor necrosis factor; autotransplantation; clinical outcome; exploratory research; chemokine cxcl10; maintenance chemotherapy; humans; human; male; female; cxcl10 protein, human
Journal Title:	Bone Marrow Transplantation
Volume:	58
Issue:	8
ISSN:	0268-3369
Publisher:	Nature Publishing Group
Date Published:	2023-08-01
Start Page:	953
End Page:	955
Language:	English
DOI:	10.1038/s41409-023-02004-5
PUBMED:	37149674
PROVIDER:	scopus
PMCID:	PMC10555486
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85158126520&doi=10.1038%2fs41409-023-02004-5&partnerID=40&md5=c40a04728f6730f8d8ab3d6bfa080d16
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208866